Integra LifeSciences (NASDAQ:IART) Shares Down 4.4% – Should You Sell?

Integra LifeSciences Holdings Co. (NASDAQ:IART)’s stock price fell 4.4% on Monday . The stock traded as low as $21.61 and last traded at $22.15. 303,470 shares traded hands during mid-day trading, a decline of 11% from the average session volume of 341,422 shares. The stock had previously closed at $23.17.

Analysts Set New Price Targets

A number of research firms have commented on IART. Morgan Stanley started coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target for the company. Truist Financial decreased their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Bank of America cut their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. Citigroup upped their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Finally, BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and an average price target of $23.00.

Integra LifeSciences Stock Down 6.3 %

The firm has a market capitalization of $1.67 billion, a P/E ratio of -241.08, a price-to-earnings-growth ratio of 0.82 and a beta of 1.16. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The stock has a fifty day moving average of $23.17 and a 200 day moving average of $22.88.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same period in the previous year, the firm earned $0.76 EPS. The firm’s quarterly revenue was down .4% on a year-over-year basis. On average, research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IART. KBC Group NV lifted its holdings in Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 1,120 shares during the last quarter. Northwest Investment Counselors LLC bought a new position in Integra LifeSciences in the 3rd quarter worth approximately $73,000. Canada Pension Plan Investment Board purchased a new position in Integra LifeSciences in the 2nd quarter valued at approximately $114,000. Allspring Global Investments Holdings LLC raised its holdings in Integra LifeSciences by 58.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after acquiring an additional 1,711 shares during the period. Finally, Centiva Capital LP purchased a new stake in shares of Integra LifeSciences during the third quarter worth $192,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.